ALNY241115C300000
- 8.88
- -3.22-26.61%
Alnylam Pharmaceuticals Newsroom
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $371
Express News | Alnylam Pharmaceuticals Inc : TD Cowen Raises Target Price to $371 From $282
TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Alnylam Canada Signs LOI From Pan-Canadian Pharmaceutical Alliance For The Public Reimbursement Of AMVUTTRA For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults
Express News | Alnylam Canada Signs Letter of Intent From Pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of Amvuttra® for the Treatment of Hereditary Transthyretin-Mediated (Hattr) Amyloidosis in Adults
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Press Release: Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
Is nuclear power becoming a new favorite for technology giants in the US stock market? Uranium producer cameco surged nearly 8% overnight; impressive Q3 performance for aviation/airlines industry! United Airlines, Delta Air Lines join hands to reach new h
Digital payment giants hit new highs! Visa financial services, american express surged by about 50% this year, mastercard rose by over 17% in the past three months.
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug
Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target
Express News | Alnylam Pharmaceuticals Inc - Helios-B Phase 3 Study Met All Primary and Secondary Endpoints
Express News | Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of Attr Amyloidosis With Cardiomyopathy
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $314
Alnylam Pharmaceuticals Is Maintained at Buy by Chardan Capital
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Hold Rating on Alnylam Pharmaceuticals Amid Vutrisiran Commercialization Challenges